Showing 1716 results
-
Press release /Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women…
-
Biography /
-
Press release /Aktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
-
Press release /Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to…
-
Press release /RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with…
-
Press release /First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
-
Press release /Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and…
-
Press release /Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow…
-
Press release /Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…